Your session is about to expire
← Back to Search
Tetracycline Antibiotic
Minocycline and Proteinuria in Diabetic Nephropathy
N/A
Waitlist Available
Led By Sharon G Adler, MD
Research Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 mos
Awards & highlights
All Individual Drugs Already Approved
Summary
This trial is testing minocycline, an antibiotic, to see if it can safely help people with Type 2 diabetes who have kidney disease. Current treatments can cause serious side effects, so a safer option is needed. Minocycline has shown promise in animal studies by protecting kidney cells from damage.
Eligible Conditions
- Kidney disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 mos
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 mos
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Other study objectives
Safety
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: MinocyclineExperimental Treatment1 Intervention
Minocycline 100 mg po bid for 6 months
Group II: PlaceboPlacebo Group1 Intervention
Placebo one tablet po bid
Find a Location
Who is running the clinical trial?
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLead Sponsor
104 Previous Clinical Trials
46,553 Total Patients Enrolled
Sharon G Adler, MDPrincipal InvestigatorLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center